ADMA Biologics stock has jumped 13% in a week, so why does the August 10 lawsuit deadline still matter?

ADMA Biologics, Inc. (NASDAQ: ADMA) faces an August 10, 2026 deadline for eligible investors seeking appointment as lead plaintiff in a securities class action covering purchases or acquisitions between August 9, 2024 and March 25, 2026. The complaint alleges that ADMA Biologics and certain current and former executives made materially misleading statements concerning revenue quality, related-party dealings and internal controls, allegations the company disputes. The legal deadline arrives only days after ADMA Biologics reported second-quarter revenue of $124.4 million, ASCENIV revenue growth of 24% and GAAP net income growth of 11%, providing investors with materially fresher operating evidence than was available when the lawsuit was filed. ADMA shares closed at $9.90 on August 7, up about 13.3% from their August 3 close, although they remain around 52% below their 52-week high. The central issue is therefore shifting from the existence of the lawsuit itself toward whether subsequent demand, cash conversion and customer-level evidence can reinforce or challenge the competing interpretations of ADMA Biologics’ historical growth.

What exactly is the August 10 ADMA Biologics class-action deadline, and who does it affect?

Kahn Swick & Foti issued an August 7 alert stating that investors who acquired ADMA Biologics securities during the August 9, 2024 to March 25, 2026 class period have until August 10 to seek appointment as lead plaintiff. The law firm’s alert specifically targets investors with losses exceeding $100,000, but the August 10 date described in the notice concerns applications for the lead-plaintiff role. It is not a court ruling on whether ADMA Biologics or any individual defendant violated securities law.

That distinction is particularly important in a securities-litigation story because procedural developments can easily be mistaken for substantive findings. ADMA Biologics‘ latest Form 10-Q describes the case as being at a preliminary stage, says the company considers the claims without merit and states that it intends to defend the action. The company also said it could not predict the outcome or reasonably estimate a potential loss and therefore had recorded no litigation accrual.

There is also a verification issue in the August 7 law-firm alert. Kahn Swick & Foti identifies the case as No. 26-cv-04793, while the complaint itself and the public District of New Jersey docket identify Mazzarino v. ADMA Biologics, Inc. et al. as Case No. 2:26-cv-06918. The public docket records the complaint as filed on June 10, 2026 against ADMA Biologics, Adam S. Grossman, Jerrold V. Grossman and former Chief Financial Officer Brad Tade. For purposes of identifying the litigation, the filed complaint and court docket provide the more precise case reference.

What does the Mazzarino complaint actually allege about ADMA Biologics and ASCENIV revenue?

The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. Its central allegations include that defendants failed to disclose what the plaintiff characterizes as an undisclosed related-party transaction, that ADMA Biologics allegedly used channel stuffing to create an appearance of revenue growth, and that internal controls were allegedly inadequate. The complaint seeks unspecified monetary damages. None of those allegations has been established by a final court judgment.

A significant part of the complaint’s narrative derives from a March 24, 2026 report published by Culper Research, which disclosed that it held a short position in ADMA Biologics. Culper alleged that reported growth was being inflated through excess product moving into distribution channels and also raised questions about a business it identified as Genesis BioPharma Services. The complaint incorporated those allegations into its theory that earlier company statements were misleading.

That origin matters analytically. A short-seller report can identify issues that merit investigation, but its allegations do not become verified facts simply because they are subsequently reproduced in a civil complaint. The relevant investment question is whether later disclosures, financial statements and observable operating trends provide evidence that supports or weakens the disputed revenue-quality thesis.

ADMA Biologics responded in March with a detailed rejection of the short report. The company said end-user demand for ASCENIV had increased for more than two years and argued that distributors maintain safety stock because patients receiving immune globulin therapy require continuity of supply. ADMA reported average ASCENIV distributor inventory coverage of 128 days on January 5 and 90 days on March 22, including agreed safety-stock levels, while inventory above those minimum levels declined from 84 days to 48 days.

ADMA Biologics also stated that no entity owned or controlled by Adam Grossman, Jerrold Grossman or the Grossman family had distributed, taken title to, possessed or been sold the company’s immune globulin products. The company further pointed to unqualified audit opinions for fiscal 2024 and fiscal 2025 concerning its financial statements and internal control over financial reporting. Those statements represent ADMA Biologics’ response to the allegations, rather than an adjudication of the underlying dispute.

Why do ADMA Biologics’ second-quarter 2026 results change the revenue-quality debate?

The August 5 results are important because they introduce another reporting period after the March short report and after the end of the proposed class period. ADMA Biologics reported second-quarter revenue of $124.4 million, up 2% from $122.0 million a year earlier, while ASCENIV revenue increased 24% to $102.9 million. BIVIGAM revenue fell 49% to $19.4 million, meaning the relatively modest group-level revenue increase concealed a much stronger shift toward ASCENIV.

That product mix had a significant profitability effect. Second-quarter gross profit increased to $86.3 million from $67.2 million and gross margin expanded to 69% from 55%. GAAP net income rose 11% to $37.8 million, adjusted EBITDA increased 22% to $61.8 million and basic earnings per share increased to $0.17 from $0.14.

For the first half, ASCENIV revenue increased 26% to $200.4 million even as BIVIGAM revenue declined 51%, leaving total revenue at $238.9 million compared with $236.8 million a year earlier. First-half gross margin expanded to 70% from 54%, while GAAP net income increased 36% to $83.1 million.

These figures do not retrospectively determine whether every historical disclosure challenged in the lawsuit was accurate. They do, however, increase the importance of the forward operating evidence. If ASCENIV utilization continues growing after distributor inventory has normalized, accompanied by collections and operating cash flow, it becomes harder to analyse the company solely through reported shipments into the distribution channel.

Management said June delivered the strongest sequential month-over-month ASCENIV utilization growth since the first half of 2024, based on distributor-reported end-user utilization. ADMA Biologics also reiterated full-year 2026 guidance for revenue of $530 million to $560 million, adjusted net income of $170 million to $200 million and adjusted EBITDA of $265 million to $300 million. Those are company forecasts rather than assured outcomes, but they create measurable benchmarks for the second half of the year.

Does ADMA Biologics’ customer concentration make distributor demand a more important proof point?

Customer concentration remains one of the most relevant financial disclosures when assessing the disagreement over channel demand. Three customers represented approximately 76% of second-quarter 2026 consolidated revenue and 79% of first-half revenue. During the first half specifically, BioCare, Inc. and Priority Healthcare Distribution, Inc., which operates as CuraScript SD Specialty Distribution, accounted for approximately 67% of consolidated revenue.

Those two customers also represented approximately 81% of ADMA Biologics’ accounts receivable at June 30, compared with approximately 87% at the end of 2025. Customer concentration itself is not evidence of channel stuffing or another securities-law violation. It does mean, however, that sell-through trends, distributor inventory movements and collection patterns carry unusual analytical weight because a relatively small number of commercial relationships account for a large portion of reported revenue and receivables.

The cash-flow statement provides a potentially important counterpoint to a simple shipment-growth narrative. ADMA Biologics generated $87.8 million of operating cash during the first six months of 2026, compared with $1.5 million during the corresponding period of 2025. The company attributed the improvement primarily to higher net income and favorable timing of accounts-receivable collections. Accounts receivable stood at $138.2 million at June 30, down from $158.4 million at December 31, while inventory increased to $239.3 million from $206.5 million.

That combination deserves continued attention. Stronger cash collection is constructive because recognized revenue ultimately needs to convert into cash, while higher inventory means investors still have reason to monitor production, product mix and future sell-through. Neither figure alone proves or disproves the lawsuit’s allegations.

How does ADMA Biologics’ balance sheet affect the investment case while litigation remains unresolved?

ADMA Biologics ended June with $136.0 million of cash and cash equivalents and working capital of approximately $452.4 million. Total debt was approximately $196.6 million, up from $72.1 million at December 31, 2025. The increase should not be interpreted in isolation as evidence of operating financial stress because ADMA borrowed $125 million under its revolving facility in March to finance an accelerated share repurchase agreement.

The company had repurchased about 13.8 million shares through June 30 during 2026, representing 5.3% of shares outstanding according to its second-quarter update. ADMA Biologics said it remained on course to complete at least $200 million of share repurchases during 2026. The capital-allocation decision increases the importance of continued operating cash generation because a business simultaneously funding commercial expansion, product development, debt service and buybacks has less tolerance for a deterioration in its core cash engine.

Litigation is also beginning to have a visible operating-cost dimension, even though no damages liability has been determined. Selling, general and administrative expenses increased to $26.7 million in the second quarter from $22.2 million a year earlier, with ADMA Biologics attributing part of the increase to higher professional and consulting fees associated with ongoing legal and related matters.

For shareholders, the more meaningful financial question is therefore not whether an unspecified damages claim can be immediately valued. ADMA itself says it cannot reasonably estimate the potential loss. The measurable issue today is whether litigation-related costs remain manageable relative to expanding ASCENIV profits and operating cash generation.

What does the ADMA stock rebound indicate about investor sentiment after second-quarter earnings?

ADMA Biologics shares closed at $9.90 on August 7, down 1.6% for the session but substantially above the $8.74 closing price recorded on August 3. That equates to a roughly 13.3% rise across the five trading sessions beginning August 3, including an 8.6% jump on August 6 following the second-quarter update.

The longer-term picture remains much less repaired. The shares are approximately 51.6% below their $20.46 52-week high and around 37% above their $7.21 52-week low. One-month performance was positive at about 8.5%, while the latest market capitalisation was approximately $2.28 billion.

The recent recovery suggests investors have been willing to give some weight to improving ASCENIV performance, margins and cash generation. It would be premature, however, to interpret the rebound as evidence that the legal and disclosure overhang has disappeared. A stock that remains roughly half below its 52-week high is still reflecting materially different expectations from those prevailing at the top of its recent valuation range.

What are the key facts investors should know about ADMA Biologics before the August 10 deadline?

• The August 10 date concerns applications to become lead plaintiff in the securities class action and is not a ruling on the merits of the case.
• The proposed class period covers ADMA Biologics securities acquired between August 9, 2024 and March 25, 2026.
• The filed complaint alleges violations of federal securities law involving revenue quality, related-party disclosure and internal controls.
• ADMA Biologics disputes the allegations and says the litigation remains preliminary and the claims are without merit.
• The complaint incorporates allegations originally advanced by Culper Research, which disclosed a short position in ADMA Biologics.
• Second-quarter ASCENIV revenue rose 24% to $102.9 million even as BIVIGAM revenue declined 49%.
• Second-quarter gross margin increased from 55% to 69%, while GAAP net income rose 11% to $37.8 million.
• First-half operating cash flow increased to $87.8 million, while accounts receivable declined from year-end levels.
• ADMA shares closed at $9.90 on August 7, up about 13.3% from August 3 but still roughly 52% below their 52-week high.
• The next meaningful evidence will come from sustained end-user ASCENIV utilization, distributor inventory trends, cash collections and progress through the securities litigation.

Can sustained ASCENIV demand and stronger cash conversion reduce ADMA Biologics’ legal overhang?

ADMA Biologics enters the August 10 deadline with a more complicated investment picture than the litigation alert alone suggests. The lawsuit is real and the allegations are material, particularly because they challenge the quality of the revenue growth that helped drive the company’s earlier valuation. But the allegations remain allegations, the case is at a preliminary stage, and ADMA Biologics has provided a detailed denial rather than conceding the disputed points.

At the same time, second-quarter results provide evidence that the operating story has not simply stopped after the March controversy. ASCENIV revenue continued growing, margins expanded sharply and first-half cash generation improved. The weakness in BIVIGAM also makes the composition of growth unusually transparent: the investment thesis is becoming progressively more dependent on ASCENIV rather than broad-based growth across the portfolio.

The strongest future evidence will therefore be operational rather than rhetorical. Sustained growth in distributor-reported end-user utilization, lower or stable channel inventory relative to demand, continued accounts-receivable conversion and delivery against the $530 million to $560 million full-year revenue range would strengthen the argument that ASCENIV has durable underlying demand. A reversal in utilization, renewed inventory accumulation, weaker collections or evidence developed through the litigation that contradicts ADMA Biologics’ disclosures would weaken that case.

The August 10 deadline is an important procedural milestone. For the ADMA Biologics investment thesis, however, the bigger test will extend well beyond Monday: whether the company’s reported ASCENIV economics increasingly reconcile across shipments, end-user use, receivables and cash.